Diabetic macular edema (DME)
- Intravitreal anti-VEGF is first-line for center-involving vision loss
- Aflibercept/bevacizumab/ranibizumab/faricimab options
- Steroid implant for selected refractory/pseudophakic cases
- Laser retains selected noncentral roles
- Optimize glycemia/BP/kidney disease
- OCT guides response and retreatment
Use at a glance
- Intravitreal anti-VEGF is first-line for center-involving vision loss
Practical pearls
- Aflibercept/bevacizumab/ranibizumab/faricimab options
Monitoring / follow-up
- Optimize glycemia/BP/kidney disease
- OCT guides response and retreatment
Escalation / refractory disease
- Steroid implant for selected refractory/pseudophakic cases
- Laser retains selected noncentral roles
Self-check
- What systemic factors are optimized in DME?
Glycemia/BP/kidney disease. - What is first-line for DME with center-involving vision loss?
Intravitreal anti-VEGF.
Drugs used for this (4)
All clinical uses · Open Diabetic macular edema (DME) in the interactive console ↗